Viking Therapeutics, Inc. cash flow to debt ratio of -203.42K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Viking Therapeutics, Inc.'s free cash flow has decreased 217.45% from $-87.79M last year to $-278.69M, signaling decreasing performance

Viking Therapeutics, Inc.'s debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability.

Viking Therapeutics, Inc.'s debt has increased relative to shareholder equity from 0.00 last year to 0.01 today, signaling weakened financials

Viking Therapeutics, Inc. has a net cash position, so leverage is healthy.

Viking Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Viking Therapeutics, Inc. has insufficient data to evaluate this check.

Viking Therapeutics, Inc.'s short-term assets of $715.60M exceed its short-term liabilities of $76.67M

Viking Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Viking Therapeutics, Inc.'s return on equity of -94.56%, is lower than 15.00%, indicating bad performance

Viking Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Viking Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Viking Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Viking Therapeutics, Inc. has negative free cash flow, indicating cash burn

Viking Therapeutics, Inc.'s yearly earnings has decreased 227.05% since last year from $-109.96M to $-359.64M, signaling decreasing performance

Viking Therapeutics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -135.79% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Viking Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Viking Therapeutics, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Viking Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Viking Therapeutics, Inc. has insufficient data to evaluate this check.

Viking Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Viking Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Viking Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Viking Therapeutics, Inc. has insufficient data to evaluate this check.

Viking Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Viking Therapeutics, Inc. has a price-to-book ratio of 9.78x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Viking Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue